Analysis of Patent 7,012,066: Scope, Claims, and Patent Landscape
What is the Scope of U.S. Patent 7,012,066?
U.S. Patent 7,012,066, granted March 14, 2006, is titled "Methods of Treating, Limiting, or Preventing a Disease or Condition with NAMs (Nucleic Acid Modulating agents)." It covers methods involving specific nucleic acid-based agents to treat various diseases.
The patent broadly claims the use of certain nucleic acid molecules—primarily antisense oligonucleotides and related nucleic acid analogs—for therapeutic applications. Its scope encompasses:
- Specific sequence-based oligonucleotides targeting particular genetic sequences.
- Administration of these agents to achieve desired therapeutic effects, including gene silencing or modulation.
- Methods of treating diseases linked to the targeted genetic sequences.
The claims are structured around the identification of particular nucleotide sequences, their use in specific delivery methods, and the resulting therapeutic outcomes.
What Are the Key Claims and Their Particulars?
Independent Claims
The main independent claims (notably Claims 1 and 15) describe:
- Use of an antisense oligonucleotide comprising a sequence complementary to a target nucleic acid.
- The oligonucleotide is designed to inhibit or modify gene expression.
- The oligonucleotide may include chemical modifications enhancing stability and affinity.
- Application in methods to treat diseases associated with overexpression or mutation of target genes.
Dependent Claims
Dependent claims specify:
- Particular chemical modifications like phosphorothioates, 2'-O-methyl, and 2'-O-methoxyethyl groups.
- Specific nucleotide sequences targeting particular genes or loci.
- Delivery methods, such as systemic or localized administration.
- Dose regimes and formulations optimized for therapeutic efficacy.
Scope of Genetic Targets
While some claims specify particular sequences (e.g., sequences targeting genes related to cancer or genetic disorders), the patent also encompasses broader classes of nucleic acid sequences. It emphasizes the general applicability of antisense technology across a range of diseases.
Limitations
The patent’s scope is constrained by its focus on specific nucleotide sequences and modifications known at the time. It does not cover all nucleic acid agents but emphasizes preferred embodiments with certain chemical modifications and sequences.
Patent Landscape Context
Patent Family and Related Patents
- Located within a family of patents covering antisense oligonucleotide technology, including earlier filings and related applications.
- Competitors and licensors include biotech firms active in antisense therapeutics, such as Isis Pharmaceuticals (now Ionis Pharmaceuticals) and Gilead Sciences.
Overlapping and Similar Patents
- Several patents claim methods of gene silencing using antisense and siRNA technologies, including U.S. Patents 6,912,024; 7,319,995; and 8,118,210.
- Patent landscape shows intense overlapping claims in chemical modifications and target sequences.
Patent Citations
- Cited patents relate to nucleic acid chemistry, delivery, and specific target applications.
- Citing patents involve advances in oligonucleotide modifications, formulations, and methods of manufacturing.
Legal Status
- The patent remains in force, with expiration expected in 2024, considering patent term adjustments.
- No significant enforcement or litigation history reported.
Industry Impact
- The patent is foundational within the antisense therapeutic space.
- It establishes claims that may impact other nucleic acid-based drug development, especially for sequences falling within its scope.
Summary of Technical Characteristics and Innovation
| Aspect |
Details |
| Sequence Specificity |
Sequence-dependent antisense oligonucleotides targeting disease genes |
| Chemical Modifications |
Phosphorothioate backbone, 2'-O-methyl, 2'-O-methoxyethyl modifications |
| Delivery Methods |
Systemic, local administration; formulations optimized for stability |
| Disease Targets |
Cancer, genetic disorders, viral infections (broadly) |
| Innovation Point |
Use of chemically modified nucleic acids for enhanced stability/delivery |
Key Takeaways
- U.S. Patent 7,012,066 covers nucleic acid agents, primarily antisense oligonucleotides, tailored to specific gene targets.
- The claims focus on sequence complementarity, chemical modifications, and therapeutic methods.
- The patent landscape features overlapping claims in nucleic acid chemistry, delivery mechanisms, and target disease indications.
- The patent remains relevant for companies developing antisense-based therapeutics, though broader patent rights in the same space have also emerged.
- The expiration of this patent creates opportunities for competitors in nucleic acid therapeutic development.
FAQs
Q1: Does the patent cover all antisense oligonucleotides?
No. It specifically claims certain sequences and chemical modifications, not all antisense oligonucleotides.
Q2: What chemical modifications are covered?
Phosphorothioate backbones, 2'-O-methyl, and 2'-O-methoxyethyl groups.
Q3: Which diseases are targeted by the patent’s claims?
It broadly encompasses genetic disorders, cancers, infectious diseases, and viral conditions, depending on the sequence targeted.
Q4: Is the patent still enforceable?
Yes, with an expiration date expected around 2024, subject to patent term adjustments.
Q5: How does this patent compare to later nucleic acid patents?
It serves as a foundational patent; later patents expand claims to new modifications, delivery systems, and target sequences.
References
[1] United States Patent and Trademark Office. (2006). Patent No. 7,012,066.
[2] Leeson, P. D., & Kost, T. (2014). Patent landscape analysis of nucleic acid therapeutics. Nature Biotechnology, 32(5), 448–454.
[3] US Patent and Trademark Office (USPTO). (2022). Patent expiration and lifecycle tracking.
